Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Targretin
Targretin 75 mg soft capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-091526 · Präparat HOS-084349
Effects of other substances on bexarotene
No formal studies to evaluate interactions with bexarotene have been conducted. On the basis of the
oxidative metabolism of bexarotene by cytochrome P450 3A4 (CYP3A4), coadministration with other
CYP3A4 substrates such as ketoconazole, itraconazole, protease inhibitors, clarithromycin and
erythromycin may theoretically lead to an increase in plasma bexarotene concentrations. Furthermore,
co-administration with CYP3A4 inducers such as rifampicin, phenytoin, dexamethasone or
phenobarbital may theoretically cause a reduction in plasma bexarotene concentrations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) phenobarbital (HOS-085617) ketoconazole (HOS-084513) dexamethasone (HOS-084535) lead (HOS-085592) itraconazole (HOS-084516) clarithromycin (HOS-084517) erythromycin (HOS-084514) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-12T12:14:00Z · SHA-256 3bf4d2f2fd7cbd6812f185953fbdb6223f58862715009080d9c1b2058c9f08b5 · Passage be5f9d9ff4d76d4b8473caec9b0e2e223aad8970f837bc7e78b263d876520dda · Zeichen 0–606 im Abschnitt
Wechselwirkungen · Trizivir
TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10
HOS-108564 · Präparat HOS-093047
9
(600 mg once daily/200 mg (UGT induction)
thrice daily)
ANTICONVULSANTS
Phenobarbital/Abacavir Interaction not studied. Insufficient data to
recommend dosage
Potential to slightly decrease adjustment.
abacavir plasma concentrations
through UGT induction.
Phenobarbital/Lamivudine Interaction not studied.
Phenobarbital/Zidovudine Interaction not studied.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage 2de843b3d98b08026fa69b1a6861021c481cac3daf97c7f32c4726be6e8068fd · Zeichen 6363–6902 im Abschnitt
Wechselwirkungen · Prandin
Prandin 0.5 mg tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-108641 · Präparat HOS-093055
Rifampicin, a potent inducer of CYP3A4, but also CYP2C8, acts both as an inducer and inhibitor of
the metabolism of repaglinide. Seven days pre-treatment with rifampicin (600 mg), followed by co-
administration of repaglinide (a single dose of 4 mg) at day seven resulted in a 50% lower AUC
(effect of a combined induction and inhibition). When repaglinide was given 24 hours after the last
rifampicin dose, an 80% reduction of the repaglinide AUC was observed (effect of induction alone).
Concomitant use of rifampicin and repaglinide might therefore induce a need for repaglinide dose
adjustment which should be based on carefully monitored blood glucose concentrations at both
initiation of rifampicin treatment (acute inhibition), following dosing (mixed inhibition and
induction), withdrawal (induction alone) and up to approximately two weeks after withdrawal of
rifampicin where the inductive effect of rifampicin is no longer present. It cannot be excluded that
other inducers, e.g. phenytoin, carbamazepine, phenobarbital, St John’s wort, may have a similar
effect.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) glucose (HOS-088412) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-05-14T02:00:00Z · SHA-256 4c973e31eb747a16f464340bcfe327b4eb470ef0597a3a9d0a9fc8e0d35f01d0 · Passage 31fab674d3b982b5678db881a9858bd54a43f38e2abad0b375f6a21302409319 · Zeichen 2816–3890 im Abschnitt
Wechselwirkungen · Prandin
Prandin 1 mg tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-108676 · Präparat HOS-093055
Rifampicin, a potent inducer of CYP3A4, but also CYP2C8, acts both as an inducer and inhibitor of
the metabolism of repaglinide. Seven days pre-treatment with rifampicin (600 mg), followed by co-
administration of repaglinide (a single dose of 4 mg) at day seven resulted in a 50% lower AUC
(effect of a combined induction and inhibition). When repaglinide was given 24 hours after the last
rifampicin dose, an 80% reduction of the repaglinide AUC was observed (effect of induction alone).
Concomitant use of rifampicin and repaglinide might therefore induce a need for repaglinide dose
adjustment which should be based on carefully monitored blood glucose concentrations at both
initiation of rifampicin treatment (acute inhibition), following dosing (mixed inhibition and
induction), withdrawal (induction alone) and up to approximately two weeks after withdrawal of
rifampicin where the inductive effect of rifampicin is no longer present. It cannot be excluded that
other inducers, e.g. phenytoin, carbamazepine, phenobarbital, St John’s wort, may have a similar
effect.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) glucose (HOS-088412) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-05-14T02:00:00Z · SHA-256 4c973e31eb747a16f464340bcfe327b4eb470ef0597a3a9d0a9fc8e0d35f01d0 · Passage 31fab674d3b982b5678db881a9858bd54a43f38e2abad0b375f6a21302409319 · Zeichen 2817–3891 im Abschnitt
Wechselwirkungen · Prandin
Prandin 2 mg tablets · Abschnitt 4.5 · PDF-Seite 25
HOS-108711 · Präparat HOS-093055
Rifampicin, a potent inducer of CYP3A4, but also CYP2C8, acts both as an inducer and inhibitor of
the metabolism of repaglinide. Seven days pre-treatment with rifampicin (600 mg), followed by co-
administration of repaglinide (a single dose of 4 mg) at day seven resulted in a 50% lower AUC
(effect of a combined induction and inhibition). When repaglinide was given 24 hours after the last
rifampicin dose, an 80% reduction of the repaglinide AUC was observed (effect of induction alone).
Concomitant use of rifampicin and repaglinide might therefore induce a need for repaglinide dose
adjustment which should be based on carefully monitored blood glucose concentrations at both
initiation of rifampicin treatment (acute inhibition), following dosing (mixed inhibition and
induction), withdrawal (induction alone) and up to approximately two weeks after withdrawal of
rifampicin where the inductive effect of rifampicin is no longer present. It cannot be excluded that
other inducers, e.g. phenytoin, carbamazepine, phenobarbital, St John’s wort, may have a similar
effect.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) glucose (HOS-088412) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-05-14T02:00:00Z · SHA-256 4c973e31eb747a16f464340bcfe327b4eb470ef0597a3a9d0a9fc8e0d35f01d0 · Passage 31fab674d3b982b5678db881a9858bd54a43f38e2abad0b375f6a21302409319 · Zeichen 2817–3891 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 15–16
HOS-108886 · Präparat HOS-093083
15
Dabigatran etexilate, Dabigatran etexilate, Clinical monitoring and/or dose
Edoxaban Edoxaban: reduction of the direct oral
Serum concentrations may be anticoagulants (DOAC) should be
increased due to P-gp inhibition considered when a DOAC
by lopinavir/ritonavir. transported by P-gp but not
metabolised by CYP3A4,
including dabigatran etexilate and
edoxaban, is co-administered with
Kaletra.
Anticonvulsants
Phenytoin Phenytoin: Caution should be exercised in
Steady-state concentrations was administering phenytoin with
moderately decreased due to Kaletra.
CYP2C9 and CYP2C19 induction
by lopinavir/ritonavir. Phenytoin levels should be
monitored when co-administering
Lopinavir: with Kaletra.
Concentrations are decreased due
to CYP3A induction by When co-administered with
phenytoin. phenytoin, an increase of Kaletra
dosage may be envisaged. Dose
adjustment has not been evaluated
in clinical practice.
Carbamazepine and Carbamazepine: Caution should be exercised in
Phenobarbital Serum concentrations may be administering carbamazepine or
increased due to CYP3A phenobarbital with Kaletra.
inhibition by lopinavir/ritonavir.
Carbamazepine and phenobarbital
Lopinavir: levels should be monitored when
Concentrations may be decreased co-administering with Kaletra.
due to CYP3A induction by
carbamazepine and phenobarbital. When co-administered with
carbamazepine or phenobarbital, an
increase of Kaletra dosage may be
envisaged. Dose adjustment has
not been evaluated in clinical
practice
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) edoxaban (HOS-086234) dabigatran etexilate (HOS-086233) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage a45fdd8825462561a02993489236d84d7e773cdb05b58085ed2d9feb61b50710 · Zeichen 23538–26612 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 52–53
HOS-109011 · Präparat HOS-093083
52
Kaletra must not be administered
once daily in combination with
phenytoin.
Carbamazepine and Carbamazepine: Caution should be exercised in
Phenobarbital Serum concentrations may be administering carbamazepine or
increased due to CYP3A phenobarbital with Kaletra.
inhibition by lopinavir/ritonavir. Carbamazepine and phenobarbital
levels should be monitored when
Lopinavir: co-administering with Kaletra.
Concentrations may be decreased When co-administered with
due to CYP3A induction by carbamazepine or phenobarbital, an
carbamazepine and phenobarbital. increase of Kaletra dosage may be
envisaged. Dose adjustment has not
been evaluated in clinical practice.
Kaletra must not be administered
once daily in combination with
carbamazepine and phenobarbital.
Lamotrigine and Lamotrigine: Patients should be monitored closely
Valproate AUC: ↓ 50% for a decreased VPA effect when
Cmax: ↓ 46% Kaletra and valproic acid or valproate
Cmin: ↓ 56% are given concomitantly.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) valproate (HOS-085955) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 7ab99d1352f73d28a2d94a0c91058c6dc39f0bd1e0fb1d81b22f720114b89a89 · Zeichen 24661–26644 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 87–88
HOS-109085 · Präparat HOS-093083
87
Rivaroxaban Rivaroxaban: Co-administration of rivaroxaban
AUC: ↑ 153% and Kaletra may increase
(Ritonavir 600 mg twice Cmax: ↑ 55% rivaroxaban exposure which may
daily) Due to CYP3A and P-gp increase the risk of bleeding.
inhibition by lopinavir/ritonavir. The use of rivaroxaban is not
recommended in patients receiving
concomitant treatment with Kaletra
(see section 4.4).
Dabigatran etexilate, Dabigatran etexilate, Clinical monitoring and/or dose
Edoxaban Edoxaban: reduction of the direct oral
Serum concentrations may be anticoagulants (DOAC) should be
increased due to Pgp inhibition by considered when a DOAC
lopinavir/ritonavir. transported by P-gp but not
metabolised by CYP3A4, including
dabigatran etexilate and edoxaban,
is co-administered with Kaletra.
Anticonvulsants
Phenytoin Phenytoin: Caution should be exercised in
Steady-state concentrations was administering phenytoin with
moderately decreased due to Kaletra.
CYP2C9 and CYP2C19 induction Phenytoin levels should be
by lopinavir/ritonavir. monitored when co-administering
with Kaletra.
Lopinavir: When co-administered with
Concentrations are decreased due phenytoin, an increase of Kaletra
to CYP3A induction by dosage may be envisaged. Dose
phenytoin. adjustment has not been evaluated
in clinical practice.
Kaletra must not be administered
once daily in combination with
phenytoin.
Carbamazepine and Carbamazepine: Caution should be exercised in
Phenobarbital Serum concentrations may be administering carbamazepine or
increased due to CYP3A phenobarbital with Kaletra.
inhibition by lopinavir/ritonavir. Carbamazepine and phenobarbital
levels should be monitored when
Lopinavir: co-administering with Kaletra.
Concentrations may be decreased When co-administered with
due to CYP3A induction by carbamazepine or phenobarbital, an
carbamazepine and phenobarbital. increase of Kaletra dosage may be
envisaged. Dose adjustment has not
been evaluated in clinical practice.
Kaletra must not be administered
once daily in combination with
carbamazepine and phenobarbital.
Lamotrigine and Lamotrigine: Patients should be monitored
Valproate AUC: ↓ 50% closely for a decreased VPA effect
Cmax: ↓ 46% when Kaletra and valproic acid or
Cmin: ↓ 56% valproate are given concomitantly.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) valproate (HOS-085955) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) rivaroxaban (HOS-086236) edoxaban (HOS-086234) dabigatran etexilate (HOS-086233) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 0668c273c88d1ae41827a69ac1504dff6543bd6b0d2a053e402140143e6219fb · Zeichen 22156–26627 im Abschnitt
Gegenanzeigen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 6
HOS-109434 · Präparat HOS-093201
• Coadministration with rifampicin, carbamazepine, long-acting barbiturates e.g., phenobarbital, and
St. John’s Wort (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage af41f6b877e5fa6678f86e38ef6c547c0cdb47a0dc9525a9cd90778700fa67ab · Zeichen 1204–1353 im Abschnitt
Gegenanzeigen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.3 · PDF-Seite 37
HOS-109526 · Präparat HOS-093201
• Coadministration with rifampicin, carbamazepine, long-acting barbiturates e.g., phenobarbital and
St. John’s Wort (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage d5b88726355ba7a830c24fd0c8a52d6a625795c060dc87674cf02cb74e061a65 · Zeichen 1204–1352 im Abschnitt
Gegenanzeigen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.3 · PDF-Seite 70
HOS-109590 · Präparat HOS-093201
• Coadministration with rifampicin, carbamazepine, long-acting barbiturates e.g., phenobarbital and
St. John’s Wort (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage d5b88726355ba7a830c24fd0c8a52d6a625795c060dc87674cf02cb74e061a65 · Zeichen 1206–1354 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-109445 · Präparat HOS-093201
Erythromycin (1 g BID) Voriconazole Cmax and AUC ↔
[CYP3A4 inhibitor]
The effect of voriconazole on
either erythromycin or
azithromycin is unknown.
Rifabutin Concomitant use of voriconazole
[potent CYP450 inducer] and rifabutin should be avoided
Voriconazole Cmax 69% unless the benefit outweighs the
300 mg QD Voriconazole AUC 78% risk.
The maintenance dose of
Compared to voriconazole 200 mg voriconazole may be increased to
300 mg QD (coadministered BID, 5 mg/kg intravenously BID or
with voriconazole 350 mg Voriconazole Cmax 4% from 200 mg to 350 mg orally
BID)* Voriconazole AUC 32% BID (100 mg to 200 mg orally
BID in patients less than 40 kg)
(see section 4.2).
Careful monitoring of full blood
Rifabutin Cmax 195% counts and adverse reactions to
300 mg QD (coadministered Rifabutin AUC 331% rifabutin (e.g., uveitis) is
with voriconazole 400 mg Compared to voriconazole 200 mg recommended when rifabutin is
BID)* BID, coadministered with
voriconazole.
Voriconazole Cmax 104%
Voriconazole AUC 87%
Rifampicin (600 mg QD) Voriconazole Cmax 93% Contraindicated (see section
[potent CYP450 inducer] Voriconazole AUC 96% 4.3)
Anti-cancer agents
Glasdegib Although not studied, voriconazole If concomitant use cannot be
[CYP3A4 substrate] is likely to increase the plasma avoided, frequent ECG
concentrations of glasdegib and monitoring is recommended (see
increase risk of QTc prolongation. section 4.4).
Tretinoin Although not studied, voriconazole Dose adjustment of tretinoin is
[CYP3A4 substrate] may increase tretinoin recommended during treatment
concentrations and increase risk of with voriconazole and after its
adverse reactions (pseudotumor discontinuation.
cerebri, hypercalcaemia).
11
Tyrosine kinase inhibitors Although not studied, voriconazole If concomitant use cannot be
(including but not limited to: may increase plasma avoided, dose reduction of the
axitinib, bosutinib, concentrations of tyrosine kinase tyrosine kinase inhibitor and
cabozantinib, ceritinib, inhibitors metabolised by CYP3A4. close clinical monitoring is
cobimetinib, dabrafenib, recommended (see section 4.4).
dasatinib, nilotinib, sunitinib,
ibrutinib, ribociclib)
[CYP3A4 substrates]
Venetoclax Although not studied, voriconazole
Concomitant administration of
[CYP3A substrate] is likely to significantly increase
voriconazole is contraindicated
the plasma concentrations of at initiation and during
venetoclax. venetoclax dose titration phase
(see section 4.3). Dose reduction
of venetoclax is required as
instructed in venetoclax
prescribing information during
steady daily dosing; close
monitoring for signs of toxicity is
recommended.
Vinca Alkaloids (including but Although not studied, voriconazole Dose reduction of vinca alkaloids
not limited to: vincristine and is likely to increase the plasma should be considered.
vinblastine) concentrations of vinca alkaloids
[CYP3A4 substrates] and lead to neurotoxicity.
Anticoagulants
Warfarin (30 mg single dose, Maximum increase in prothrombin Close monitoring of prothrombin
coadministered with 300 mg time was approximately 2-fold. time or other suitable
BID voriconazole) anticoagulation tests is
[CYP2C9 substrate] recommended, and the dose of
anticoagulants should be adjusted
Other oral coumarins Although not studied, voriconazole accordingly.
(including but not limited to: may increase the plasma
phenprocoumon, concentrations of coumarins that
acenocoumarol) may cause an increase in
[CYP2C9 and CYP3A4 prothrombin time.
substrates]
Anticonvulsants
Carbamazepine and Although not studied, Contraindicated (see section
long-acting barbiturates carbamazepine and long-acting 4.3)
(including but not limited to: barbiturates are likely to
phenobarbital, mephobarbital) significantly decrease plasma
[potent CYP450 inducers] voriconazole concentrations.
Phenytoin Concomitant use of voriconazole
[CYP2C9 substrate and potent and phenytoin should be avoided
CYP450 inducer] unless the benefit outweighs the
risk. Careful monitoring of
300 mg QD Voriconazole Cmax 49% phenytoin plasma levels is
Voriconazole AUC 69% recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): axitinib (HOS-109448) ceritinib (HOS-086215) dasatinib (HOS-086217) cobimetinib (HOS-109451) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) vinblastine (HOS-086220) glasdegib (HOS-109446) vincristine (HOS-086219) azithromycin (HOS-088112) phenprocoumon (HOS-091031) dabrafenib (HOS-109452) venetoclax (HOS-086143) tretinoin (HOS-109447) lead (HOS-085592) prothrombin (HOS-085093) sunitinib (HOS-109453) erythromycin (HOS-084514) ribociclib (HOS-109454) tyrosine (HOS-108875) acenocoumarol (HOS-109456) cabozantinib (HOS-109450) phenytoin (HOS-084531) warfarin (HOS-085950) bosutinib (HOS-109449) mephobarbital (HOS-109457) nilotinib (HOS-086218) ibrutinib (HOS-086226)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 92969ff5c9d1e7ffb4a2f7eaf265abd9d2899e7061ac52ea8adefc4d660b4316 · Zeichen 4932–11582 im Abschnitt
Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 43–44
HOS-109538 · Präparat HOS-093201
43
Anticoagulants
Warfarin (30 mg single dose, Maximum increase in prothrombin Close monitoring of prothrombin
coadministered with 300 mg time was approximately 2-fold. time or other suitable
BID voriconazole) anticoagulation tests is
[CYP2C9 substrate] recommended, and the dose of
anticoagulants should be adjusted
Other oral coumarins Although not studied, voriconazole accordingly.
(including but not limited to: may increase the plasma
phenprocoumon, concentrations of coumarins that
acenocoumarol) may cause an increase in
[CYP2C9 and CYP3A4 prothrombin time.
substrates]
Anticonvulsants
Carbamazepine and Although not studied, Contraindicated (see section
long-acting barbiturates carbamazepine and long-acting 4.3)
(including but not limited to: barbiturates are likely to
phenobarbital, mephobarbital) significantly decrease plasma
[potent CYP450 inducers] voriconazole concentrations.
Phenytoin Concomitant use of voriconazole
[CYP2C9 substrate and potent and phenytoin should be avoided
CYP450 inducer] unless the benefit outweighs the
risk. Careful monitoring of
300 mg QD Voriconazole Cmax 49% phenytoin plasma levels is
Voriconazole AUC 69% recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) phenprocoumon (HOS-091031) prothrombin (HOS-085093) acenocoumarol (HOS-109456) phenytoin (HOS-084531) warfarin (HOS-085950) mephobarbital (HOS-109457)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 5ae9bbe0daf742daaf2a160c7d91f0c8d54a2ad8a7e98684c6f63198d04c2a65 · Zeichen 10221–11996 im Abschnitt
Wechselwirkungen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 75–76
HOS-109603 · Präparat HOS-093201
75
Tyrosine kinase inhibitors Although not studied, voriconazole If concomitant use cannot be
(including but not limited to: may increase plasma avoided, dose reduction of the
axitinib, bosutinib, concentrations of tyrosine kinase tyrosine kinase inhibitor and
cabozantinib, ceritinib, inhibitors metabolised by CYP3A4. close clinical monitoring is
cobimetinib, dabrafenib, recommended (see section 4.4).
dasatinib, nilotinib, sunitinib,
ibrutinib, ribociclib)
[CYP3A4 substrates]
Venetoclax Although not studied, voriconazole
Concomitant administration of
[CYP3A substrate] is likely to significantly increase
voriconazole is contraindicated
the plasma concentrations of at initiation and during
venetoclax. venetoclax dose titration phase
(see section 4.3). Dose reduction
of venetoclax is required as
instructed in venetoclax
prescribing information during
steady daily dosing; close
monitoring for signs of toxicity is
recommended.
Vinca Alkaloids (including but Although not studied, voriconazole Dose reduction of vinca alkaloids
not limited to: vincristine and is likely to increase the plasma should be considered.
vinblastine) concentrations of vinca alkaloids
[CYP3A4 substrates] and lead to neurotoxicity.
Anticoagulants
Warfarin (30 mg single dose, Maximum increase in prothrombin Close monitoring of prothrombin
coadministered with 300 mg time was approximately 2-fold. time or other suitable
BID voriconazole) anticoagulation tests is
[CYP2C9 substrate] recommended, and the dose of
anticoagulants should be adjusted
Other oral coumarins Although not studied, voriconazole accordingly.
(including but not limited to: may increase the plasma
phenprocoumon, concentrations of coumarins that
acenocoumarol) may cause an increase in
[CYP2C9 and CYP3A4 prothrombin time.
substrates]
Anticonvulsants
Carbamazepine and Although not studied, Contraindicated (see section
long-acting barbiturates carbamazepine and long-acting 4.3)
(including but not limited to: barbiturates are likely to
phenobarbital, mephobarbital) significantly decrease plasma
[potent CYP450 inducers] voriconazole concentrations.
Phenytoin Concomitant use of voriconazole
[CYP2C9 substrate and potent and phenytoin should be avoided
CYP450 inducer] unless the benefit outweighs the
risk. Careful monitoring of
300 mg QD Voriconazole Cmax 49% phenytoin plasma levels is
Voriconazole AUC 69% recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): axitinib (HOS-109448) ceritinib (HOS-086215) dasatinib (HOS-086217) cobimetinib (HOS-109451) phenobarbital (HOS-085617) carbamazepine (HOS-085618) vinblastine (HOS-086220) vincristine (HOS-086219) phenprocoumon (HOS-091031) dabrafenib (HOS-109452) venetoclax (HOS-086143) lead (HOS-085592) prothrombin (HOS-085093) sunitinib (HOS-109453) ribociclib (HOS-109454) tyrosine (HOS-108875) acenocoumarol (HOS-109456) cabozantinib (HOS-109450) phenytoin (HOS-084531) warfarin (HOS-085950) bosutinib (HOS-109449) mephobarbital (HOS-109457) nilotinib (HOS-086218) ibrutinib (HOS-086226)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage f6b81055f3c718e14857cfd38d70a912e61bf8acd5f789552e442ecbfbe65b67 · Zeichen 7792–11614 im Abschnitt
Wechselwirkungen · Tracleer
Tracleer 62.5 mg film-coated tablets Tracleer 125 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-109926 · Präparat HOS-093279
Rifampicin: Co-administration in 9 healthy subjects for 7 days of bosentan 125 mg twice daily with
rifampicin, a potent inducer of CYP2C9 and CYP3A4, decreased the plasma concentrations of
bosentan by 58%, and this decrease could achieve almost 90% in an individual case. As a result, a
significantly reduced effect of bosentan is expected when it is co-administered with rifampicin.
Concomitant use of rifampicin and Tracleer is not recommended. Data on other CYP3A4 inducers,
e.g., carbamazepine, phenobarbital, phenytoin and St. John’s wort are lacking, but their concomitant
administration is expected to lead to reduced systemic exposure to bosentan. A clinically significant
reduction of efficacy cannot be excluded.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) lead (HOS-085592) bosentan (HOS-086291) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-25T15:01:00Z · SHA-256 eddfcd40df26bd01c2c7847da53c544c94e0bafb8bcc62374b5c7788669470bc · Passage a30be20bb22004903f151f7e54a6dd8796bf6a4aaf6a5fc5d7df9c1a1589bcfd · Zeichen 3248–3970 im Abschnitt
Wechselwirkungen · Tracleer
Tracleer 32 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 31
HOS-109979 · Präparat HOS-093279
Rifampicin: Co-administration in 9 healthy subjects for 7 days of bosentan 125 mg twice daily with
rifampicin, a potent inducer of CYP2C9 and CYP3A4, decreased the plasma concentrations of
bosentan by 58%, and this decrease could achieve almost 90% in an individual case. As a result, a
significantly reduced effect of bosentan is expected when it is co-administered with rifampicin.
Concomitant use of rifampicin and Tracleer is not recommended. Data on other CYP3A4 inducers,
e.g., carbamazepine, phenobarbital, phenytoin and St. John’s wort are lacking, but their concomitant
administration is expected to lead to reduced systemic exposure to bosentan. A clinically significant
reduction of efficacy cannot be excluded.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) lead (HOS-085592) bosentan (HOS-086291) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-25T15:01:00Z · SHA-256 eddfcd40df26bd01c2c7847da53c544c94e0bafb8bcc62374b5c7788669470bc · Passage a30be20bb22004903f151f7e54a6dd8796bf6a4aaf6a5fc5d7df9c1a1589bcfd · Zeichen 3191–3913 im Abschnitt
Wechselwirkungen · Glivec
Glivec 100 mg film-coated tablets Glivec 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-110221 · Präparat HOS-093339
Substances that are inducers of CYP3A4 activity (e.g. dexamethasone, phenytoin, carbamazepine,
rifampicin, phenobarbital, fosphenytoin, primidone or Hypericum perforatum, also known as St.
John’s Wort) may significantly reduce exposure to Glivec, potentially increasing the risk of
therapeutic failure. Pretreatment with multiple doses of rifampicin 600 mg followed by a single
400 mg dose of Glivec resulted in decrease in Cmax and AUC(0-∞) by at least 54% and 74%, of the
respective values without rifampicin treatment. Similar results were observed in patients with
malignant gliomas treated with Glivec while taking enzyme-inducing anti-epileptic drugs (EIAEDs)
such as carbamazepine, oxcarbazepine and phenytoin. The plasma AUC for imatinib decreased by
73% compared to patients not on EIAEDs. Concomitant use of rifampicin or other strong CYP3A4
inducers and imatinib should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosphenytoin (HOS-110222) phenobarbital (HOS-085617) carbamazepine (HOS-085618) dexamethasone (HOS-084535) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) primidone (HOS-090551)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-12T09:28:00Z · SHA-256 838bc114dc50fcc5141e52ce7cbac64366b6fd4a03bb5a5e7a5ec09cf8be0b00 · Passage bb17575a294e1c6ea67d8805646bff3038e1cfd96e17f699d0cea24ccaeb8458 · Zeichen 875–1767 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-111251 · Präparat HOS-093485
Cytochrome P450 inducers
A CYP3A4 inducer, rifampicin, reduced tadalafil AUC by 88 %, relative to the AUC values for
tadalafil alone (10 mg). This reduced exposure can be anticipated to decrease the efficacy of tadalafil;
the magnitude of decreased efficacy is unknown. Other inducers of CYP3A4 such as phenobarbital,
phenytoin and carbamazepine, may also decrease plasma concentrations of tadalafil.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage f70610d1a079bc8d0f58b67b203cd4c636120190b428a07b196b990ea06625a5 · Zeichen 1540–1940 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 20
HOS-111299 · Präparat HOS-093485
Cytochrome P450 inducers
A CYP3A4 inducer, rifampicin, reduced tadalafil AUC by 88 %, relative to the AUC values for
tadalafil alone (10 mg). This reduced exposure can be anticipated to decrease the efficacy of tadalafil;
the magnitude of decreased efficacy is unknown. Other inducers of CYP3A4 such as phenobarbital,
phenytoin and carbamazepine, may also decrease plasma concentrations of tadalafil.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage f70610d1a079bc8d0f58b67b203cd4c636120190b428a07b196b990ea06625a5 · Zeichen 1485–1885 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 10 mg film-coated tablets CIALIS 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 35
HOS-111338 · Präparat HOS-093485
Cytochrome P450 inducers
A CYP3A4 inducer, rifampicin, reduced tadalafil AUC by 88 %, relative to the AUC values for
tadalafil alone (10 mg). This reduced exposure can be anticipated to decrease the efficacy of tadalafil;
the magnitude of decreased efficacy is unknown. Other inducers of CYP3A4 such as phenobarbital,
phenytoin and carbamazepine, may also decrease plasma concentrations of tadalafil.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage f70610d1a079bc8d0f58b67b203cd4c636120190b428a07b196b990ea06625a5 · Zeichen 1541–1941 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.